Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Mid and smallcaps outperform
Tue, 5 Apr 11:30 am

Benchmark indices in the Indian stock market have slipped further into the negative territory during the last two hours of trade. Stocks from consumer durables and healthcare space are trading firm and those from IT and banking space are trading weak.

The BSE-Sensex is down by 118 points while NSE-Nifty is trading 37 points below yesterday's closing. BSE Midcap and BSE Small capindices are up by 0.2% and 0.7% respectively. The rupee is trading at 44.41 to the US dollar.

Pharma stocks are trading firm led by Ranbaxy and Biocon. As per a leading financial daily, Pfizer has agreed to sell its Capsugel business to KKR, a private equity firm for about US$ 2.4 bn in cash. The pharmaceutical company plans to use the proceeds of the dealings to buy back its shares. This is in addition to the repurchase programme of US$ 5 bn announced earlier. Capsugel had about US$ 750 m revenues last year and made more than 180 bn pills. As a result of the deal, Pfizer has lowered its 2011 revenue forecast from US$ 66 bn - US$ 68 bn to US$ 65.2 bn - US$ 67.2 bn. The 2012 revenue target has been revised from US$ 63 bn- US$ 65.5 bn to US$ 62.2 bn- US$ 64.7 bn. According to Pfizer, the deal is expected to get completed during third quarter subject to approval from the US, European Union and other regulators.

Engineering stocks are trading mixed with Areva T&D and Finolex trading firm while Suzlon Energy and Welspun Corp are trading weak. As per a leading financial daily, power equipment maker BHEL is exploring opportunities for setting up of gas turbine projects in Japan. As per a company spokesperson, BHEL along with its joint venture partner General Electric is looking at setting up of gas turbines in the country as these can be set up quickly and have a smaller gestation period. After the earthquake in Japan, the country's 11 nuclear reactors out of 54 are not working. This has led to a power shortfall of 13,000 Mw. The problem with the nuclear reactors has prompted Tepco, the Japanese power firm that owns the Fukushima plant, to order 10 truck mounted gas turbines of 25 Mw capacity each from GE. The aftermath of the earthquake has provided a huge opportunity for manufacturers of gas turbines. It may be noted that business from West Asia accounts for less than 1% of BHEL's revenues.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid and smallcaps outperform". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.